10-Q: Acelyrin Reports Q1 2025 Financial Results, Merger with Alumis Approved

Acelyrin announces Q1 2025 financial results, including a net loss of $55.3 million, and confirms stockholder approval of the merger with Alumis.

Summary

• Acelyrin, Inc. reported a net loss of $55.3 million for the first quarter ended March 31, 2025, compared to a net loss of $35.0 million for the same period in 2024.
• Research and development expenses decreased to $42.1 million from $58.0 million year-over-year, primarily due to reduced activity under the Restructuring Plan.
• General and administrative expenses decreased to $17.7 million from $24.7 million year-over-year, with an increase in professional consulting fees offset by a decrease in employee salaries and benefits.
• As of March 31, 2025, the company had cash, cash equivalents, restricted cash, and short-term marketable securities totaling $411.1 million.
• Stockholders approved the merger with Alumis Inc. on May 13, 2025, and the company expects to close the merger in the second quarter of 2025.
• The company has delayed initiation of the Phase 3 LONGITUDE program for lonigutamab until the closing of the Merger.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the merger approval is positive, increased losses and delayed clinical trials temper the outlook. The company's future is heavily dependent on the success of the merger and the development of lonigutamab.

Positives

• The company's cash position remains strong at $411.1 million as of March 31, 2025.
• The company has reduced operating expenses through the Restructuring Plan.
• Stockholder approval of the merger with Alumis Inc. provides a path forward for the company.
• The company expects to substantially complete the wind-down of activities related to the izokibep program by the end of the second quarter of 2025.

Negatives

• The company incurred a net loss of $55.3 million for Q1 2025, an increase from the $35.0 million loss in Q1 2024.
• The company has delayed initiation of the Phase 3 LONGITUDE program for lonigutamab until the closing of the Merger.
• The company has stopped all development of izokibep and provided notice of termination to Affibody AB (Affibody) of our license agreement with Affibody for izokibep.

Risks

• The merger with Alumis is subject to closing conditions and may not be completed.
• The company is subject to business uncertainties and contractual restrictions while the merger is pending.
• The company has a limited operating history and has incurred substantial losses since its inception.
• The company's clinical trials may reveal significant adverse events.
• The company faces competition from entities with greater resources and experience.
• The company's business depends entirely on the success of its product candidates.
• The company may not be able to obtain and maintain sufficient intellectual property protection.
• The company may have conflicts with its current or future licensors or collaborators.
• The company has been named a defendant in a purported securities class action lawsuit.

Future Outlook

The company expects to close the merger with Alumis in the second quarter of 2025 and will re-evaluate the development program for lonigutamab.

Management Comments

• The company has delayed initiation of the Phase 3 LONGITUDE program until the closing of the Merger and that we planned to re-evaluate the development program for lonigutamab to enable potential confirmation of its differentiation in a capital efficient manner.

Industry Context

The announcement comes amid increasing competition in the biopharmaceutical industry, particularly in the development of novel treatments for immunological indications. The company's strategic decision to focus on lonigutamab reflects a capital-allocation decision in response to the competitive landscape.

Comparison to Industry Standards

• The company's decision to delay the Phase 3 LONGITUDE program contrasts with competitors like argenx SE, Lassen Therapeutics, Roche, Roivant, Sling Therapeutics, Inc., and Viridian Therapeutics, Inc., some of which are in late-stage development for TED.
• The company's focus on subcutaneous delivery of lonigutamab aims to differentiate from the existing intravenously-administered anti-IGF-1R agent, Tepezza.
• The company's restructuring plan and focus on lonigutamab reflect a trend in the biopharmaceutical industry to prioritize promising assets and streamline operations.

Corporate Governance

Legal Proceedings

• The company is a defendant in a purported securities class action lawsuit.
• Richard Lawrence, a purported stockholder of the Company, filed a complaint in the Supreme Court of the State of New York against us and the individual members of the Board, captioned Lawrence v. Acelyrin, Inc., et al.
• Michael Kent, a purported stockholder of the Company, filed a complaint in the Supreme Court of the State of New York against us and the individual members of the Board, captioned Kent v. Acelyrin, Inc., et al.

Stakeholder Impact

• Shareholders: Approval of the merger with Alumis, but uncertainty remains regarding the future value of the combined entity.
• Employees: Workforce reduction as part of the Restructuring Plan.
• Customers: Potential for new treatments for Thyroid Eye Disease, but development timelines are uncertain.
• Suppliers: Changes in manufacturing agreements and potential for supply chain disruptions.
• Creditors: No significant impact mentioned in the document.

Next Steps

• Close the merger with Alumis Inc. in the second quarter of 2025.
• Re-evaluate the development program for lonigutamab.
• Substantially complete the wind-down of activities related to the izokibep program by the end of the second quarter of 2025.

Key Dates

Keywords

Acelyrin, Alumis, Merger, Lonigutamab, Izokibep, Financial Results, Clinical Trials, Thyroid Eye Disease, TED, R&D, Restructuring Plan, Net Loss